Physician profile
Shikha S Sundaram
NPI 1891750881
$47,251.34
in general payments reported to CMS, 2019-2025
7 companies · $6,330 in 2025
The $6,330 reported for 2025 was more than what 92% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.89 · 2020: $5,129 · 2022: $9,729 · 2023: $16K · 2024: $9,548 · 2025: $6,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,840 · Honoraria: $2,490 · Food and Beverage: $411 · Education: $11.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,076.50 |
| Travel and Lodging | $12,472.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,840.00 |
| Honoraria | $2,490.00 |
| Food and Beverage | $410.61 |
| Education | $11.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $16,053.31 | 2022-2023 | Livmarli |
| Albireo Pharma, INC. | $13,013.23 | 2023-2024 | Bylvay |
| Ipsen Biopharmaceuticals, INC | $6,477.61 | 2023-2025 | Bylvay |
| Abbott Laboratories | $6,462.50 | 2023 | Ensite Precision |
| Intercept Pharmaceuticals, INC. | $5,128.69 | 2020 | |
| Biocompatibles, INC. | $92.89 | 2019 | |
| Travere Therapeutics, INC. | $23.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shikha Sundaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.